18F-PSMA-1007 is a fluorine-18 labeled PSMA-targeting ligand combining a peptidomimetic binding motif with a radiolabeled prosthetic group. The structure is optimized for receptor affinity and metal-free radionuclide attachment. Researchers investigate its kinetics, binding constants, and metabolic stability in model systems. Applications include tracer-design studies, PSMA-epitope mapping, and radioligand-structure optimization.
CAT No: ta-586
Synonyms/Alias:18F-PSMA 1007; (2~{S})-2-[[(2~{S})-6-[[(2~{S})-2-[[4-[[[(2~{S})-2-[[(2~{S})-2-[(6-fluoranylpyridin-3-yl)carbonylamino]-5-oxidanyl-5-oxidanylidene-pentanoyl]amino]-5-oxidanyl-5-oxidanylidene-pentanoyl]amino]methyl]phenyl]carbonylamino]-3-naphthalen-2-yl-propanoyl]amino]-1-oxidanyl-1-oxidanylidene-hexan-2-yl]carbamoylamino]pentanedioic acid; 2093321-18-5; SCHEMBL20180889; F-PSMA 1007; PSMA-1007?; AT43725; 9OT
18F-Psma 1007 is a radiolabeled small molecule designed for the selective targeting of the prostate-specific membrane antigen (PSMA), a transmembrane protein highly expressed in prostate cancer cells and certain other malignancies. As a member of the class of fluorine-18 labeled PSMA ligands, it combines the high affinity of PSMA-targeting motifs with the favorable imaging characteristics of the positron-emitting isotope fluorine-18. Its chemical structure enables effective binding to PSMA-expressing cells, making it an important tool for investigating PSMA biology, radiotracer development, and molecular imaging strategies in preclinical research settings. The compound's unique properties have made it a prominent choice for studies focused on advancing the understanding of PSMA as a biomarker and target in oncology and related biomedical fields.
Molecular imaging research: The compound serves as a key probe in preclinical molecular imaging studies, particularly those utilizing positron emission tomography (PET) to visualize PSMA expression in vitro and in vivo. Its high specificity and favorable pharmacokinetics allow for the detailed mapping of PSMA-positive tissues, supporting the evaluation of tumor localization, receptor density, and tracer biodistribution in animal models. This capability is essential for validating new imaging protocols and optimizing the performance of PSMA-targeted radiotracers.
Radiotracer development and validation: 18F-Psma 1007 is widely employed in the development and comparative assessment of novel PSMA-targeted PET tracers. Researchers use it as a benchmark compound to evaluate the binding affinity, selectivity, and imaging characteristics of new PSMA ligands. Its established behavior in biological systems provides a reference point for structure-activity relationship studies and for refining the design of next-generation imaging agents with improved pharmacological profiles.
Target engagement studies: The radiolabeled ligand is instrumental in quantifying target engagement and occupancy of PSMA in various experimental systems. By enabling precise measurement of tracer uptake and displacement in the presence of competitive inhibitors or therapeutic candidates, it supports the assessment of drug-target interactions, receptor saturation, and the specificity of PSMA-targeted interventions. These studies are critical for early-stage drug discovery and for elucidating mechanisms of action in PSMA-related research.
Biodistribution and pharmacokinetics analysis: The compound is frequently used to characterize the in vivo biodistribution, clearance, and metabolic stability of PSMA-targeted agents. By tracking the radiotracer in animal models, researchers can obtain quantitative data on tissue uptake, organ distribution, and elimination pathways, informing the optimization of dosing regimens and the selection of lead compounds for further development. Such analyses are fundamental to the preclinical evaluation of imaging probes and targeted delivery systems.
Tumor model characterization: 18F-Psma 1007 is employed in the characterization of PSMA-expressing tumor xenografts and genetically engineered mouse models. Its application enables the non-invasive assessment of tumor burden, heterogeneity, and progression in response to experimental interventions. The ability to longitudinally monitor PSMA expression dynamics provides valuable insights into tumor biology, therapeutic response, and resistance mechanisms, facilitating translational research in oncology and molecular imaging.
2. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
4. Implications of ligand-receptor binding kinetics on GLP-1R signalling
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More